EUVIMEDEUVIMED entdecken
Multizentrische Studie

Therapeutic drug monitoring of polymyxin B cerebrospinal fluid concentrations in patients with carbapenem-resistant Gram-negative bacteria-induced central nervous system infection

Peile Wang, Shaohua Liu, Xia He, Wang Miao, Tongwen Sun, Jing Yang iD

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae193 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Peile Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Drug Monitoring, Polymyxin B, Anti-Bacterial Agents, Gram-Negative Bacterial Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: National Key Research and Development Program of China, United Fund of National Natural Science Foundation of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Central nervous system (CNS) infections caused by carbapenem-resistant Gram-negative bacteria (CR-GNB) present a major health and economic burden worldwide. This multicentre prospective study aimed to assess the feasibility and usefulness of CSF therapeutic drug monitoring (TDM) after intrathecal/intraventricular administration of polymyxin B in patients with CNS infections.

Methods

Forty-two patients treated with intrathecal/intraventricular administration of polymyxin B against CR-GNB-induced CNS infections were enrolled. CSF trough level (Cmin) was collected beginning on Day 2 post-polymyxin B initiation and thereafter. The primary outcomes were clinical cure and 28-day all-cause mortality.

Results

All patients started with intrathecal/intraventricular administration of polymyxin B at a dose of 5 g/day, corresponding to a median CSF Cmin of 2.93 mg/L (range, 0.21–25.74 mg/L). Clinical cure was 71.4%, and the median CSF Cmin of this group was higher than that of clinical failure group [3.31 (IQR, 1.73–5.62) mg/L versus 2.25 (IQR, 1.09–4.12) mg/L; P = 0.011]. In addition, with MICs ≤ 0.5 mg/L, maintaining polymyxin B CSF Cmin above 2.0 mg/L showed a higher clinical cure rate (P = 0.041). The 28-day all-cause mortality rate was 31.0% and had no association with CSF Cmin.

Conclusions

After intrathecal/intraventricular administration of polymyxin B, CSF concentrations fluctuated considerably inter- and intra-individual. Polymyxin B CSF Cmin above 2.0 mg/L was associated with clinical cure when MICs were ≤ 0.5 mg/L, and the feasibility of TDM warrants additional clinical studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug MonitoringPolymyxin BAnti-Bacterial AgentsGram-Negative Bacterial InfectionsCarbapenemsGram-Negative BacteriaHumansMaleFemaleMiddle AgedProspective StudiesAgedAdultCentral Nervous System InfectionsInjections, SpinalTreatment OutcomeMicrobial Sensitivity TestsCerebrospinal Fluid

Substanzen

Polymyxin BAnti-Bacterial AgentsCarbapenems

Autor:innen und Institutionen

  • Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou, China.
  • Henan Province Engineering Research Center for Application and Translation of Precision Clinical Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Department of General Intensive Care Unit, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Henan Province Engineering Research Center for Critical Care Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Department of Neuro-Intensive Care Unit, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

ORCID-Profile: Jing Yang

Förderung

  • National Key Research and Development Program of China
  • United Fund of National Natural Science Foundation of China
  • National Natural Science Foundation of China
  • Central Government Guides Local Science and Technology Development
  • Medical Science and Technology Tackling Plan Provincial and Ministerial Major Projects of Henan Province
  • Scientific Research and Innovation Excellence Team of First Affiliated Hospital of Zhengzhou University
  • National Key R&D Program of China

Zitieren

APA

Wang, P., Liu, S., He, X., Miao, W., Sun, T., & Yang, J. (2024). Therapeutic drug monitoring of polymyxin B cerebrospinal fluid concentrations in patients with carbapenem-resistant Gram-negative bacteria-induced central nervous system infection. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae193

Vancouver

Wang P, Liu S, He X, Miao W, Sun T, Yang J. Therapeutic drug monitoring of polymyxin B cerebrospinal fluid concentrations in patients with carbapenem-resistant Gram-negative bacteria-induced central nervous system infection. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae193

BibTeX
@article{Wang2024,
  author = {Wang, Peile and Liu, Shaohua and He, Xia and Miao, Wang and Sun, Tongwen and Yang, Jing},
  title = {Therapeutic drug monitoring of polymyxin B cerebrospinal fluid concentrations in patients with carbapenem-resistant Gram-negative bacteria-induced central nervous system infection},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae193}
}
Kostenlos starten →